Last updated: February 11, 2009
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Trial Status Unknown
Phase
3
Condition
Leukemia
Treatment
N/AClinical Study ID
NCT00149162
P030441
AOM 03142
Ages < 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age: 0 to 18 years
Prior untreated acute myeloid leukemia (AML) of following cytological types : FAB M0,M1, M2, M4, M4 eosinophil, M5, M6, M7, without FAB classification or showingmyelodysplasia (blasts > 20 %)
Isolated myeloid sarcoma
Achieved complete remission
No HLA identical family donor, except for the patients with t(8;21)
No contraindication for the use of interleukin-2
Exclusion
Exclusion Criteria:
Trisomy 21
Promyelocytic leukemia (M3) or M3 variations
Secondary AML
Study Design
Total Participants: 580
Study Start date:
March 01, 2005
Estimated Completion Date:
March 31, 2012
Study Description
Connect with a study center
Children Armand Trousseau Hospital
Paris,
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.